Exscientia Streamlines Operations, Prioritizes AI-Driven Drug Discovery
Exscientia, AI-generated pipeline, drug discovery, staff reduction, operational efficiency, biotechnology, pharmaceutical industry
Pfizer’s Continuous Cost-Cutting: A $4B Savings Drive Extended to 2027
Pfizer, cost-cutting, savings drive, 2027, pharmaceutical industry, restructuring, efficiency, profitability.
Bicycle Therapeutics Gears Up for Future Milestones with $555 Million Capital Infusion
Bicycle Therapeutics, funding, catalysts, biotechnology, drug development, clinical trials, investors, capital infusion, milestones.
Takeda Ventures into Molecular Glue Degraders with Degron Collaboration
Takeda, Degron, molecular glue degraders, pharmaceutical collaboration, targeted protein degradation, drug discovery.
Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns
Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.
Merck KGaA Evades Legal Action Following DOJ Collaboration on China Export Investigation
Merck KGaA, DOJ, China, export scheme, cooperation, investigation, prosecution avoidance
Revitalizing Cancer Therapy: UK Biotech Acquires Kyowa Kirin’s Former Drug for Epstein-Barr-Related Diseases
UK Biotech, Kyowa Kirin, cancer drug, Epstein-Barr virus, EBV-driven diseases, drug acquisition, therapy revival.
Cytokinetics’ Royalty Agreement Dampens Merger and Acquisition Hopes, Say Investors
Cytokinetics, Merger and Acquisition (M&A), Royalty Agreement, Investors, Biotech Industry
RNA Startup ReNAgade Acquired by Competitor Following Mega-Round Funding
ReNAgade, RNA, startup, acquisition, competitor, mega-round funding, launch
Pharmaceutical Companies Prevail in 340B Case as Appeals Court Upholds Discount Restrictions
340B program, drugmakers, discounts, Appeals Court, ruling, healthcare, pharmaceuticals, hospitals, clinics.